Quetaz

Schizophrenia. Manic & depressive episodes associated w/ bipolar disorder. Maintenance treatment of bipolar I disorder (manic, mixed or depressed episode) in combination w/ mood stabilizers (lithium or valproate).

Adult Schizophrenia Administer bid. Total daily dose: 50 mg (day 1), 100 mg (day 2), 200 mg (day 3) & 300 mg (day 4). Dose range from day 4 onwards: 300-450 mg daily. May adjust dose to 150-750 mg range daily. Manic episodes associated w/ bipolar disorder Administer bid. Total daily dose: 100 mg (day 1), 200 mg (day 2), 300 mg (day 3) & 400 mg (day 4), up to 800 mg daily by day 6 in increments of 200 mg daily. May adjust dose to 200-800 mg range daily. Usual effective dose range: 400-800 mg daily. Depressive episodes associated w/ bipolar disorder Administer once daily at bedtime. Dose titration: 50 mg (day 1), 100 mg (day 2), 200 mg (day 3) & 300 mg (day 4). May titrate to 400 mg on day 5 & up to 600 mg by day 8. Maintenance treatment of bipolar I disorder in combination w/ mood stabilizers (lithium or valproate) Administer bid. Total dose: 400-800 mg daily. Hepatic impairment Initially 25 mg daily. May be increased daily w/ 25-50 mg daily increments.

May be taken with or without food.

Hypersensitivity.

Discontinue treatment if NMS occur. Consider dose reduction or discontinuation if signs & symptoms of tardive dyskinesia appear; dose reduction or more gradual titration if orthostatic hypotension occurs especially in patients w/ underlying CV disease. Not for treatment of dementia-related psychosis. Increased risk of suicidal thoughts, self-harm & suicide; potential risk of suicide-related events after abrupt cessation of treatment. Monitor patients w/ history of suicide related events, or those exhibiting significant degree of suicidal ideation; DM or risk factors for DM for worsening of glucose control. NMS manifested as hyperthermia, altered mental status, muscular rigidity, autonomic instability & increased creatinine phosphokinase; hyperglycemia &/or development or exacerbation of diabetes associated w/ ketoacidosis or coma; orthostatic hypotension & related dizziness; cardiomyopathy & myocarditis; seizures; somnolence & related symptoms eg, sedation; wt gain; increased LDL & total cholesterol; asymptomatic, transit, & reversible increases in serum transaminases, principally ALT; increased incidence of extrapyramidal symptoms; dysphagia. Observe patients for signs & symptoms of hyperglycemia eg, polydipsia, polyuria, polyphagia & weakness. Increased occurrence of accidental injury (fall) especially in elderly. Lens changes w/ long-term therapy. Decreased total & free thyroxine w/ higher dosage. Acute w/drawal symptoms eg, insomnia, nausea, vomiting, dizziness & irritability after abrupt cessation of therapy. Patients w/ known CV & cerebrovascular disease, or other conditions predisposing to hypotension; history of seizures; current diagnosis or prior history of related disease w/ cholinergic effect eg, urinary retention, priapism, clinically significant prostatic hypertrophy, intestinal obstruction or related conditions, increased IOP or narrow angle glaucoma; at risk for aspiration pneumonia. Monitor wt regularly. Reassess treatment in patients w/ suspected cardiomyopathy or myocarditis. Give thyroid replacement therapy in some patients who experienced increased TSH. Manage lipid changes. Concomitant use w/ medications w/ anticholinergic (muscarinic) effects. 3rd trimester of pregnancy. Lactation. Carefully monitor neonates exposed to antipsychotics during 3rd trimester of pregnancy for extrapyramidal &/or w/drawal symptoms. Childn & adolescents. Elderly.

Somnolence, sedation, asthenia, lethargy, dizziness, dry mouth, constipation, increased ALT, wt gain, dyspepsia, abdominal pain, postural hypotension, pharyngitis.

Concomitant use w/ other centrally acting medicinal products & alcohol; medications w/ anticholinergic (muscarinic) effects. Increased AUC w/ potent CYP3A4 inhibitors eg, erythromycin, fluconazole, itraconazole & ketoconazole. Increased clearance w/ potent CYP3A4 inducers eg, carbamazepine & phenytoin. Electrolyte imbalance & increased QT interval w/ risperidone.

Antipsychotics

N05AH04 - quetiapine ; Belongs to the class of diazepines, oxazepines and thiazepines antipsychotics.

S